Alexander Drilon MD

171 posts

Alexander Drilon MD

Alexander Drilon MD

@alexdrilon

Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center

New York Katılım Ekim 2011
213 Takip Edilen4.3K Takipçiler
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos
Elizabeth McKenna@ElizSMcKenna

Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon doi.org/10.1158/2159-8… @MSKCancerCenter

English
2
2
23
4.3K
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-appro…
English
1
30
103
16.7K
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!
Sandra Misale@Sandra_Misale

I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM

English
0
3
19
4.8K
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.
Alexander Drilon MD tweet media
Cancer Discovery@CD_AACR

Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. bit.ly/45HB06K #ASCO23

English
0
16
44
8.1K
Alexander Drilon MD retweetledi
Sandra Misale
Sandra Misale@Sandra_Misale·
Out today in @CD_AACR our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper shorturl.at/EOPT8 and a thread👇:
English
20
41
211
0
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
@FawziAbuRous Thanks! The medians for larotrecrinib DoR and PFS have not yet been reached. (Median follow up was quoted here instead)
English
1
0
0
0
Fawzi Abu Rous, MD
Fawzi Abu Rous, MD@FawziAbuRous·
6. Update on Larotrectinib in #NSCLC presented by @alexdrilon ➡️RR 83% ➡️mPFS 14.9 mo ➡️mOS 40.7 mo ➡️mDOR 12.9 mo ➡️AEs to remember: weight gain and inc LFTs
Fawzi Abu Rous, MD tweet mediaFawzi Abu Rous, MD tweet media
English
2
0
4
0
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
Excellent work from the Klebanoff lab on TCR development for an HLA-A*03:01 restricted public neoantigen generated in the context of a PIK3CA H1047L catalytic subunit hotspot mutation. rdcu.be/cMjvb
Nature Medicine@NatureMedicine

A high-throughput platform to find rare #Tcells that recognize shared cancer #neoantigens identifies TCRs specific for a conserved and therapeutically actionable epitope in mutant PIK3CA, a common driver oncogene @KlebanoffLab @MSKCancerCenter @parkerici nature.com/articles/s4159…

English
0
1
9
0
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
RETi resistance in lung, thyroid & other cancers can be complex. This paper includes insights into the serial kinetics of resistance acquisition, the potential emergence of RET wild type populations & the frequency of polyclonal resistance. Proud to be part of this team!
English
0
7
52
0
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world.
JCO Precision Oncology@JCOPO_ASCO

.@alexdrilon et al. report on first analysis of the efficacy & safety of larotrectinib in pts with TRK fusion–positive lung cancer from a registrational data set. ORR of 73% ub 15 evaluable pts w OS of 40.7 months. Larotrectinib was well tolerated. fal.cn/3lTFs

English
7
55
197
0
Alexander Drilon MD retweetledi
Alison Schram
Alison Schram@AliSchram·
Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to @ASCO for the opportunity to present, @GarridoLagunaMD for an excellent discussion, collaborators, and patients. #ASCO2021
Alison Schram tweet mediaAlison Schram tweet mediaAlison Schram tweet mediaAlison Schram tweet media
English
6
35
122
0
Alexander Drilon MD retweetledi
Alison Schram
Alison Schram@AliSchram·
I’m honored to be among the #ConquerCancer Grant & Award Class of 2021 (CDA) and 2018 (YIA). Donors make these research opportunities possible. Give to the @ASCO CONQUERS CANCER Fund to help fuel the next generation of researchers bit.ly/ASCOCONQUERSCA… #ASCO21
Conquer Cancer, the ASCO Foundation@ConquerCancerFd

Retweet this #ASCO21 #ConquerCancer collage and tag the doctors you see! Your gift to the #ASCOCONQUERSCANCER Fund supports Grant & Award recipients from around the globe 🌍🌎🌏 bit.ly/ASCOCONQUERSCA…

English
4
7
69
0
Alexander Drilon MD retweetledi
RETpositive
RETpositive@RETpositive·
RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with @LUNGevity and a generous donation-matching program, we hope to fund lifesaving research. Join us at retpositive.org #RETcancer
RETpositive tweet media
English
1
15
32
0
Alexander Drilon MD
Alexander Drilon MD@alexdrilon·
Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. google.com/amp/s/finance.…
Manhattan, NY 🇺🇸 English
3
19
95
0
Alexander Drilon MD retweetledi
Natasha Rekhtman MD PhD
Natasha Rekhtman MD PhD@natasharekhtman·
MET IHC is back from the dead! We wrote it off as a biomarker, but pl see latest study from our group lead by @alexdrilon & @RobinGuo5 which found MET expression to predict TKI response in MET Ex 14-altered NSCLC. Twists & turns of the ever-evolving NSCLC biomarker story!
Natasha Rekhtman MD PhD tweet media
English
4
19
67
0

Keşfet

@YoninaMG @AlexiaIasonos @HopkinsMedicine @hopkinskimmel @Sandra_Misale @AhernandoCalvo @CD_AACR @ASCO